Literature DB >> 31330511

Predictors of 90-Day Restart of Renal Replacement Therapy after Discontinuation of Continuous Renal Replacement Therapy, a Prospective Multicenter Study.

Susanne Stads1,2, K Merijn Kant3, Margriet F C de Jong4, Wouter de Ruijter5, Christa M Cobbaert6, Michiel G H Betjes7, Diederik Gommers8, Heleen M Oudemans-van Straaten9.   

Abstract

BACKGROUND: Restart of renal replacement therapy (RRT) after initial discontinuation of continuous RRT (CRRT) is frequently needed. The aim of the present study was to evaluate whether renal markers after discontinuation of CRRT can predict restart of RRT within 90 days.
METHODS: Prospective multicenter observational study in 90 patients, alive, still on the intensive care unit at day 2 after discontinuation of CRRT for expected recovery with urinary neutrophil gelatinase-associated lipocalin (NGAL) available. The endpoint was restart of RRT within 90 days. Baseline and renal characteristics were compared between outcome groups no restart or restart of RRT. Logistic regression and receiver operator characteristic curve analysis were performed to determine the best predictive and discriminative variables.
RESULTS: Restart of RRT was needed in 32/90 (36%) patients. Compared to patients not restarting, patients restarting RRT demonstrated a higher day 2 urinary NGAL, lower day 2 urine output, and higher incremental creatinine ratio (day 2/0). In multivariate analysis, only incremental creatinine ratio (day 2/0) remained independently associated with restart of RRT (OR 5.28, 95% CI 1.45-19.31, p = 0.012). The area under curve for incremental creatinine ratio to discriminate for restart of RRT was 0.76 (95% CI 0.64-0.88). The optimal cutoff was 1.49 (95% CI 1.44-1.62).
CONCLUSION: In this prospective multicenter study, incremental creatinine ratio (day 2/0) was the best predictor for restart of RRT. Patients with an incremental creatinine ratio at day 2 of 1.5 times creatinine at discontinuation are likely to need RRT within 90 days. These patients might benefit from nephrological follow-up. The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Acute kidney injury; Continuous renal replacement therapy; Discontinuation; Neutrophil gelatinase-associated lipocalin

Mesh:

Substances:

Year:  2019        PMID: 31330511      PMCID: PMC6878749          DOI: 10.1159/000501387

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  34 in total

1.  The 90-day mortality and the subsequent renal recovery in critically ill surgical patients requiring acute renal replacement therapy.

Authors:  Yu-Feng Lin; Wen-Je Ko; Tzong-Shinn Chu; Yih-Sharng Chen; Vin-Cent Wu; Yung-Ming Chen; Ming-Shiou Wu; Yung-Wei Chen; Ching-Wei Tsai; Chih-Chung Shiao; Wen-Yi Li; Fu-Chang Hu; Pi-Ru Tsai; Tun-Jun Tsai; Kwan-Dun Wu
Journal:  Am J Surg       Date:  2009-09       Impact factor: 2.565

2.  Predictive utilities of neutrophil gelatinase-associated lipocalin (NGAL) in severe sepsis.

Authors:  Wei Chang; Shang Zhu; Chun Pan; Jian-Feng Xie; Song-Qiao Liu; Hai-Bo Qiu; Yi Yang
Journal:  Clin Chim Acta       Date:  2018-03-20       Impact factor: 3.786

3.  Increased risk of death and de novo chronic kidney disease following reversible acute kidney injury.

Authors:  Ion D Bucaloiu; H Lester Kirchner; Evan R Norfolk; James E Hartle; Robert M Perkins
Journal:  Kidney Int       Date:  2011-12-07       Impact factor: 10.612

4.  Novel urinary biomarkers and the early detection of acute kidney injury after open cardiac surgeries.

Authors:  Said M Elmedany; Salah S Naga; Rania Elsharkawy; Rabab S Mahrous; Ahmed I Elnaggar
Journal:  J Crit Care       Date:  2017-04-06       Impact factor: 3.425

5.  The urine protein NGAL predicts renal replacement therapy, but not acute kidney injury or 90-day mortality in critically ill adult patients.

Authors:  Sara Nisula; Runkuan Yang; Kirsi-Maija Kaukonen; Suvi T Vaara; Anne Kuitunen; Jyrki Tenhunen; Ville Pettilä; Anna-Maija Korhonen
Journal:  Anesth Analg       Date:  2014-07       Impact factor: 5.108

6.  Performance of urinary NGAL and L-FABP in predicting acute kidney injury and subsequent renal recovery: a cohort study based on major surgeries.

Authors:  Xian-Fei Zeng; Jun-Min Li; Yun Tan; Zhu-Feng Wang; Yong He; Jiang Chang; Hong Zhang; Hua Zhao; Xiao Bai; Fei Xie; Juan Sun; Yan Zhang
Journal:  Clin Chem Lab Med       Date:  2014-05       Impact factor: 3.694

7.  Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury.

Authors:  Sean M Bagshaw; Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen M Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  J Crit Care       Date:  2008-04-18       Impact factor: 3.425

8.  Plasma neutrophil gelatinase-associated lipocalin predicts recovery from acute kidney injury following community-acquired pneumonia.

Authors:  Nattachai Srisawat; Raghavan Murugan; Minjae Lee; Lan Kong; Melinda Carter; Derek C Angus; John A Kellum
Journal:  Kidney Int       Date:  2011-06-15       Impact factor: 10.612

9.  Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis.

Authors:  An Zhang; Ying Cai; Peng-Fei Wang; Jian-Ning Qu; Zhen-Chun Luo; Xiao-Dong Chen; Bin Huang; Yi Liu; Wen-Qi Huang; Jing Wu; Yue-Hui Yin
Journal:  Crit Care       Date:  2016-02-16       Impact factor: 9.097

Review 10.  Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis.

Authors:  Sebastian J Klein; Anna K Brandtner; Georg F Lehner; Hanno Ulmer; Sean M Bagshaw; Christian J Wiedermann; Michael Joannidis
Journal:  Intensive Care Med       Date:  2018-03-14       Impact factor: 17.440

View more
  1 in total

Review 1.  Current Approach to Successful Liberation from Renal Replacement Therapy in Critically Ill Patients with Severe Acute Kidney Injury: The Quest for Biomarkers Continues.

Authors:  Helmut Schiffl; Susanne M Lang
Journal:  Mol Diagn Ther       Date:  2020-10-24       Impact factor: 4.074

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.